Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus
| dc.rights.license | open | en_US |
| dc.contributor.author | MALLET, Vincent | |
| dc.contributor.author | PARLATI, Lucia | |
| dc.contributor.author | MARTININO, Alessandro | |
| dc.contributor.author | SCARANO PEREIRA, Juan Pablo | |
| dc.contributor.author | NAVAS JIMENEZ, Carmen | |
| dc.contributor.author | SAKKA, Mehdi | |
| dc.contributor.author | BOUAM, Samir | |
| dc.contributor.author | RETBI, Aurelia | |
| dc.contributor.author | KRASTEVA, Donika | |
| dc.contributor.author | MERITET, Jean Francois | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | SCHWARZINGER, Michael | |
| dc.contributor.author | THABUT, Dominique | |
| dc.contributor.author | RUFAT, Pierre | |
| dc.contributor.author | BONNEFONT-ROUSSELOT, Dominique | |
| dc.contributor.author | SOGNI, Philippe | |
| dc.contributor.author | POL, Stanislas | |
| dc.contributor.author | TSOCHATZIS, Emmanuel | |
| dc.contributor.author | DEMOSTHENES RESEARCH, Group | |
| dc.date.accessioned | 2021-12-06T09:25:50Z | |
| dc.date.available | 2021-12-06T09:25:50Z | |
| dc.date.issued | 2021-10-01 | |
| dc.identifier.issn | 1600-0641 (Electronic) 0168-8278 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/123985 | |
| dc.description.abstractEn | BACKGROUND AND AIMS: There are uncertainties on the burden of liver disease in patients with type-2 diabetes (T2D). METHODS: We measured adjusted hazard ratios of liver disease progression to hepatocellular cancer and/or decompensated cirrhosis in a 2010-2020 retrospective, bicentric, longitudinal, cohort of 52,066 hospitalized patients with T2D. RESULTS: Mean age was 64±14 years and 58% were men. Alcohol use disorders accounted for 57% of liver-related complications and were associated with all liver-related risk factors. Non-metabolic liver-related risk factors accounted for 37% of the liver burden. T2D control was not associated with liver disease progression. The incidence (95% confidence interval) of liver-related complications and of competing mortality were 3.9 (3.5-4.3) and 27.8 (26.7-28.9) per 1000 person-years at risk, respectively. The cumulative incidence of liver disease progression exceeded the cumulative incidence of competing mortality only in the presence of a well-identified risk factors of liver disease progression, including alcohol use. The incidence of hepatocellular cancer was 0.3 (95% CI, 0.1-0.5) per 1000 person-year in patients with obesity and it increased with age. The adjusted hazard ratios of liver disease progression were 55.7 (40.5-76.6), 3.5 (2.3-5.2), 8.9 (6.9-11.5), and 1.5 (1.1-2.1), for alcoholic liver disease, alcohol use disorders without alcoholic liver disease, non-metabolic liver-related risk factors, and obesity, respectively. The attributable fractions of alcohol use disorders, non-metabolic liver risk-related risk factors, and obesity to the liver burden were 55%, 14%, and 7%, respectively. CONCLUSIONS: In this analysis of data from two hospital-based cohorts of patients with T2D, alcohol use disorders, rather than obesity, contributed to most of the liver burden. These results suggest that patients with T2D should be advised to drink minimal amounts of alcohol. LAY SUMMARY: • There is uncertainty on the burden of liver-related complications in patients with type-2 diabetes • We studied the risks of liver cancer and complications of liver disease in over 50,000 patients with type-2 diabetes • We found that alcohol was the main factor associated with complications of liver disease • This finding has major implications on the alcohol advice given to patients with type-2 diabetes. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Type-2 diabetes | |
| dc.subject.en | Hepatocellular carcinoma | |
| dc.subject.en | Cirrhosis | |
| dc.subject.en | Alcohol use disorders | |
| dc.subject.en | Non-alcoholic liver disease | |
| dc.subject.en | Non-alcoholic steatohepatitis | |
| dc.title.en | Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.jhep.2021.09.030 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 34606913 | en_US |
| bordeaux.journal | Journal of Hepatology | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03466693 | |
| hal.version | 1 | |
| hal.date.transferred | 2021-12-06T09:25:52Z | |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Hepatology&rft.date=2021-10-01&rft.eissn=1600-0641%20(Electronic)%200168-8278%20(Linking)&rft.issn=1600-0641%20(Electronic)%200168-8278%20(Linking)&rft.au=MALLET,%20Vincent&PARLATI,%20Lucia&MARTININO,%20Alessandro&SCARANO%20PEREIRA,%20Juan%20Pablo&NAVAS%20JIMENEZ,%20Carmen&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||